NASDAQ · Analyst Forecast

Viridian Therapeutics, Inc. (VRDN) Stock Forecast & Price Target

$30.06 NASDAQ: VRDN Market Cap $3.41B

Price as of Nov 17, 2026 close · Analyst estimates retrieved Nov 11, 2026 · Source: Financial Modeling Prep (analyst estimates) (methodology)

Revenue and earnings estimates published by analysts covering Viridian Therapeutics, Inc. (VRDN), and the range of their price targets. Everything on this page is a forecast made by other people — DeltaScreener does not produce estimates or targets of its own.

For Viridian Therapeutics, Inc., analysts forecast revenue rising from $85.43M in 2025 to $1.30B in 2030; the average estimate for 2030 earnings per share is $3.57; with published estimates ranging from $2.00 to $6.57; 11 analysts contribute to these figures. These are forecasts published by analysts, not results.

Analyst price targets

MeasureValue
Current priceWhat the share trades at now.$30.06
Consensus targetThe average of the price targets analysts have published.$37.00
Median targetThe middle target, less affected by a single outlier.$39.00
Highest targetThe most optimistic published target.$43.00
Lowest targetThe most pessimistic published target.$26.00
Difference from priceHow far the consensus target sits from today’s price.+23.1%

A price target is one analyst's forecast of where a share might trade, usually over twelve months. Targets are frequently revised, they disagree with each other, and they are not a measure of what a company is worth.

Revenue forecast (USD)

The spread between low and high is how far analysts disagree, which is usually a better guide than the average alone.

YearLowAverageHighAnalysts
2025$75.07M$85.43M$134.48M11
2026$65.90M$75.13M$90.10M11
2027$266.86M$314.19M$396.96M11
2028$492.64M$678.27M$1.43B11
2029$645.94M$976.98M$1.61B5
2030$856.45M$1.30B$2.13B5

Earnings per share forecast

YearLowAverageHighAnalysts
2025−$4.21−$3.53−$3.1011
2026−$3.95−$3.55−$3.2511
2027−$2.47−$2.09−$1.4611
2028−$0.92$0.19$3.0511
2029$1.10$1.96$3.605
2030$2.00$3.57$6.575

Viridian Therapeutics, Inc. (VRDN) forecast — frequently asked questions

What is the analyst price target for Viridian Therapeutics, Inc.?

Analysts covering Viridian Therapeutics, Inc. (VRDN) have a consensus price target of $37.00, 23.1% above the current price of $30.06. Published targets range from $26.00 to $43.00. A price target is a forecast, not a measure of value, and targets are revised often.

What are analysts forecasting for Viridian Therapeutics, Inc.'s earnings?

The average analyst estimate for Viridian Therapeutics, Inc. (VRDN) earnings per share in 2030 is 3.57, with individual estimates between 2.00 and 6.57.

How much revenue is Viridian Therapeutics, Inc. expected to make?

Analysts forecast Viridian Therapeutics, Inc. (VRDN) revenue of $1.30B in 2030, based on 5 published estimates.

How many analysts cover VRDN?

11 analysts contribute estimates for Viridian Therapeutics, Inc. (VRDN). Thin coverage makes an average less reliable.

Analyst forecasts for other Biotechnology stocks

VRTX forecastREGN forecastMRNA forecastRVMD forecastROIV forecastINSM forecastUTHR forecastINCY forecastALNY forecastASND forecastAll Biotechnology stocks

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.